{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:51:41Z","timestamp":1775544701878,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>In der Onkologie kommt der Pr\u00e4vention eine Schl\u00fcsselrolle zur Senkung von Krankheitsentstehung, Krankheitslast und Mortalit\u00e4t zu. Prim\u00e4r\u2011, Sekund\u00e4r- und Terti\u00e4rpr\u00e4vention sind als komplement\u00e4re Ebenen zu verstehen, deren Potenzial bislang unzureichend ausgesch\u00f6pft ist. Die Prim\u00e4rpr\u00e4vention adressiert modifizierbare Risikofaktoren wie Tabak- und Alkoholkonsum, Adipositas, Bewegungsmangel, UV-Exposition und onkogene Infektionen. Sch\u00e4tzungen zufolge k\u00f6nnten in Europa rund 40\u202f% der Krebsneuerkrankungen durch konsequente prim\u00e4rpr\u00e4ventive Ma\u00dfnahmen vermieden werden. Die Sekund\u00e4rpr\u00e4vention umfasst qualit\u00e4tsgesicherte Krebsfr\u00fcherkennungsprogramme, deren Wirksamkeit belegt ist, deren Inanspruchnahme jedoch weiterhin begrenzt bleibt. Aktuelle Entwicklungen betreffen u.\u202fa. die Einf\u00fchrung einer organisierten Lungenkrebsfr\u00fcherkennung f\u00fcr definierte Hochrisikopopulationen. Mit der zunehmenden Zahl von Krebs\u00fcberlebenden gewinnt die Terti\u00e4rpr\u00e4vention weiter an Relevanz; strukturierte, multimodale und multiprofessionelle Nachsorge, Rehabilitation und Survivorship-Programme sind essenziell zur Reduktion von Rezidiven sowie langfristigen somatischen und psychosozialen Folgen. Eine wirksame Krebspr\u00e4vention erfordert die systematische Verankerung evidenzbasierter Ma\u00dfnahmen in Versorgung, Forschung und Gesundheitspolitik. Medizinisch-wissenschaftliche Fachgesellschaften leisten einen aktiven Beitrag zur strategischen Weiterentwicklung.<\/jats:p>","DOI":"10.1007\/s00108-026-02073-w","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:18:18Z","timestamp":1772705898000},"page":"62-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pr\u00e4vention und Fr\u00fcherkennung in der Onkologie","Cancer prevention and screening"],"prefix":"10.1007","volume":"67","author":[{"given":"Minna","family":"Voigtlaender","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Stoelzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2073_CR1","unstructured":"https:\/\/www.krebshilfe.de\/fileadmin\/Downloads\/PDFs\/Stellungnahmen\/Memorandum_der_Deutschen_Krebshilfe_und_des_Deutschen_Krebsforschungszentrums_zur_Krebs-Praeventionsforschung_in_Deutschland.pdf"},{"issue":"8","key":"2073_CR2","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan\u00a0B et\u00a0al (2016) Body Fatness and Cancer - Viewpoint of the IARC Working Group. N Engl J Med 375(8):794\u2013798","journal-title":"N Engl J Med"},{"issue":"6","key":"2073_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1001\/jamainternmed.2016.1548","volume":"176","author":"SC Moore","year":"2016","unstructured":"Moore\u00a0SC et\u00a0al (2016) Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern Med 176(6):816\u2013825","journal-title":"JAMA Intern Med"},{"key":"2073_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2026.101592","volume":"63","author":"C Espina","year":"2026","unstructured":"Espina\u00a0C et\u00a0al (2026) European Code Against Cancer 5th edition: 14 ways you can help prevent cancer. The Lancet Regional Health Europe 63:101592","journal-title":"The Lancet Regional Health Europe"},{"key":"2073_CR5","unstructured":"https:\/\/www.krebshilfe.de\/fileadmin\/Downloads\/PDFs\/PRESSE\/Nationaler_Krebspr\u00e4ventionsgipfel_2025_-_Handlungsempfehlungen.pdf"},{"key":"2073_CR6","first-page":"455","volume":"122","author":"L Klimeck","year":"2025","unstructured":"Klimeck\u00a0L et\u00a0al (2025) Fecal occult blood tests for colorectal cancer screening in routine medical care: A longitudinal analysis from Germany. Dtsch Arztebl Int 122:455\u2013460","journal-title":"Dtsch Arztebl Int"},{"key":"2073_CR7","first-page":"655","volume":"122","author":"L Buschmann","year":"2025","unstructured":"Buschmann\u00a0L et\u00a0al (2025) Participation in the German mammography screening program: An analysis of data from the NAKO Health Study. Dtsch Arztebl Int 122:655\u2013662","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"2073_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ De Koning","year":"2020","unstructured":"De Koning\u00a0HJ et\u00a0al (2020) Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 382(6):503\u2013513","journal-title":"N Engl J Med"},{"key":"2073_CR9","doi-asserted-by":"crossref","unstructured":"Sinn\u00a0M, Wolters\u00a0F, von\u00a0Grundherr\u00a0J, Evers\u00a0C, F\u00fchres\u00a0H, Kodalle\u00a0O, Scholz\u00a0I (2026) Next Generation Survivorship: Bausteine f\u00fcr eine multiprofessionelle Versorgung nach Krebs. Forum 41:40\u201346","DOI":"10.1007\/s12312-025-01523-0"},{"issue":"1","key":"2073_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa2502760","volume":"393","author":"KS Courneya","year":"2025","unstructured":"Courneya\u00a0KS et\u00a0al (2025) Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. N Engl J Med 393(1):13\u201325","journal-title":"N Engl J Med"},{"issue":"16","key":"2073_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70039","volume":"131","author":"MA Mollica","year":"2025","unstructured":"Mollica\u00a0MA et\u00a0al (2025) Defining concepts in cancer survivorship. Cancer 131(16):e70039","journal-title":"Cancer"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02073-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:57:49Z","timestamp":1775541469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02073-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":11,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2073"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02073-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"11 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Voigtlaender: MV erhielt in den letzten drei Jahren Honorare von AstraZeneca, BeiGene, Janssen, Bristol Myers Squibb, Pfizer sowie Reisef\u00f6rderung zu wissenschaftlichen Kongressen von CSL Behring, Jazz Pharmaceuticals. M.\u00a0Sinn: MS erhielt in den letzten drei Jahren Honorare von Astellas, Conphymed, Falk, Jazz Pharma, Roche sowie institutionelle Forschungszuwendungen von Amgen, Astra Z, Beigene, BMS, B\u00f6hringer Ingelheim, GSK, MSD. J.\u00a0Gebauer, F.\u00a0Stoelzel, B.\u00a0Kempf und N.\u00a0Skoetz: Keine potenziellen Interessenkonflikte.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}